Oragenics Advances Concussion Treatment with Phase IIa Trial Approval in Australia
March 10, 2026 — Oragenics receives approval for Phase IIa trial of ONP-002, an intranasal neurosteroid for concussion treatment, with data expected by 2026. Learn about this breakthrough in neurological care.